Literature DB >> 16307358

Prevention of nephropathy in patients with type 2 diabetes mellitus.

Antonios H Tzamaloukas1, Glen H Murata.   

Abstract

The rising incidence of type 2 diabetes mellitus and of its complications will make it the most important health care challenge in the first quarter of the 21st Century. Diabetic nephropathy left unchecked will overwhelm the renal resources. Simple methods (proper diet and exercise, prevention of obesity) are successful in preventing type 2 diabetes in the great majority of the persons at risk. In patients with established type 2 diabetes, nephropathy can be prevented or greatly delayed by strict metabolic control, strict control of blood pressure using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as the first line of drugs, tight control of serum lipids using statins as indicated, low protein diet, avoidance of smoking and other nephrotoxic influences, prevention of abnormalities in calcium/phosphorus metabolism, and prevention of renal anemia by the early use of erythropoietin. Current research offers the promise of definitive prevention of both type 2 diabetes and diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16307358     DOI: 10.1007/s11255-005-2394-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  36 in total

1.  Diabetes, obesity, and the brain.

Authors:  Michael W Schwartz; Daniel Porte
Journal:  Science       Date:  2005-01-21       Impact factor: 47.728

2.  Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes.

Authors:  Robert W Schrier; Raymond O Estacio; Anne Esler; Philip Mehler
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

Authors:  R O Estacio; B W Jeffers; N Gifford; R W Schrier
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

5.  Population genetics of CAPN10 and GPR35: implications for the evolution of type 2 diabetes variants.

Authors:  J Vander Molen; L M Frisse; S M Fullerton; Y Qian; L Del Bosque-Plata; R R Hudson; A Di Rienzo
Journal:  Am J Hum Genet       Date:  2005-02-04       Impact factor: 11.025

6.  Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.

Authors:  Chariclia Gouva; Petros Nikolopoulos; John P A Ioannidis; Kostas C Siamopoulos
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

7.  Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial.

Authors:  M Ravid; D Brosh; Z Levi; Y Bar-Dayan; D Ravid; R Rachmani
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

8.  Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis.

Authors:  B L Kasiske; R S Kalil; J Z Ma; M Liao; W F Keane
Journal:  Ann Intern Med       Date:  1993-01-15       Impact factor: 25.391

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?

Authors:  Pernille Poulsen; Gitte Andersen; Mogens Fenger; Torben Hansen; Søren M Echwald; Aage Vølund; Henning Beck-Nielsen; Oluf Pedersen; Allan Vaag
Journal:  Diabetes       Date:  2003-01       Impact factor: 9.461

View more
  3 in total

Review 1.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-09       Impact factor: 2.370

2.  Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska; Monika Młot-Michalska
Journal:  Int Urol Nephrol       Date:  2009-01-31       Impact factor: 2.370

3.  p22phox C242T gene polymorphism and overt diabetic nephropathy: a meta-analysis of 1,452 participants.

Authors:  Yan-Yan Li; Ge Gong; Hong-Yu Geng; Yun Qian
Journal:  Korean J Intern Med       Date:  2016-12-08       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.